Argus restated their buy rating on shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in a research report released on Tuesday. The firm currently has a $92.95 price target on the pharmaceutical company’s stock, down from their prior price target of $115.00.

VRTX has been the subject of several other reports. Robert W. Baird reiterated a buy rating and set a $115.00 target price on shares of Vertex Pharmaceuticals in a research report on Monday, January 9th. Jefferies Group LLC reiterated a buy rating and set a $102.00 target price on shares of Vertex Pharmaceuticals in a research report on Wednesday, November 30th. Maxim Group reiterated a hold rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, January 17th. Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a hold rating to a buy rating and set a $83.00 target price for the company in a research report on Tuesday, December 27th. Finally, Vetr lowered shares of Vertex Pharmaceuticals from a strong-buy rating to a buy rating and set a $85.33 target price for the company. in a research report on Tuesday, December 6th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $100.39.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 91.92 on Tuesday. The stock’s 50 day moving average is $89.12 and its 200 day moving average is $85.20. The firm’s market capitalization is $22.84 billion. Vertex Pharmaceuticals has a 52-week low of $71.46 and a 52-week high of $103.73.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, January 25th. The pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.06. Vertex Pharmaceuticals had a negative net margin of 6.76% and a negative return on equity of 2.15%. The business earned $458.71 million during the quarter, compared to analyst estimates of $453.40 million. During the same period in the previous year, the business posted $0.17 earnings per share. On average, equities research analysts forecast that Vertex Pharmaceuticals will post $1.62 EPS for the current year.

Your IP Address:

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 6,500 shares of the business’s stock in a transaction on Wednesday, December 21st. The shares were sold at an average price of $74.16, for a total transaction of $482,040.00. Following the transaction, the director now directly owns 274,725 shares of the company’s stock, valued at approximately $20,373,606. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Joshua S. Boger sold 8,000 shares of the business’s stock in a transaction on Wednesday, January 11th. The shares were sold at an average price of $82.48, for a total transaction of $659,840.00. Following the transaction, the director now directly owns 276,225 shares in the company, valued at $22,783,038. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,500 shares of company stock worth $2,126,370. 1.90% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of VRTX. American International Group Inc. increased its position in shares of Vertex Pharmaceuticals by 1.7% in the third quarter. American International Group Inc. now owns 113,555 shares of the pharmaceutical company’s stock worth $9,903,000 after buying an additional 1,939 shares during the last quarter. Princeton Capital Management Inc. increased its position in shares of Vertex Pharmaceuticals by 0.9% in the third quarter. Princeton Capital Management Inc. now owns 25,549 shares of the pharmaceutical company’s stock worth $2,228,000 after buying an additional 227 shares during the last quarter. Manning & Napier Advisors LLC increased its position in shares of Vertex Pharmaceuticals by 12.2% in the third quarter. Manning & Napier Advisors LLC now owns 142,540 shares of the pharmaceutical company’s stock worth $12,430,000 after buying an additional 15,550 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of Vertex Pharmaceuticals by 2.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 6,492,221 shares of the pharmaceutical company’s stock worth $566,187,000 after buying an additional 144,397 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in shares of Vertex Pharmaceuticals by 195.6% in the third quarter. HighTower Advisors LLC now owns 8,554 shares of the pharmaceutical company’s stock worth $748,000 after buying an additional 5,660 shares during the last quarter. 94.85% of the stock is currently owned by institutional investors and hedge funds.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.